Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Short Interest Update

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) saw a large decrease in short interest during the month of February. As of February 27th, there was short interest totaling 99,192 shares, a decrease of 21.0% from the February 12th total of 125,617 shares. Based on an average daily volume of 13,625 shares, the days-to-cover ratio is currently 7.3 days. Currently, 0.2% of the company’s shares are short sold. Currently, 0.2% of the company’s shares are short sold. Based on an average daily volume of 13,625 shares, the days-to-cover ratio is currently 7.3 days.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Millennium Management LLC bought a new position in Innate Pharma in the fourth quarter worth $36,000. OLD Mission Capital LLC bought a new position in Innate Pharma during the 4th quarter valued at about $50,000. Finally, Jane Street Group LLC bought a new position in Innate Pharma during the fourth quarter valued at approximately $162,000. Hedge funds and other institutional investors own 0.16% of the company’s stock.

Analyst Ratings Changes

IPHA has been the subject of several research analyst reports. BTIG Research assumed coverage on shares of Innate Pharma in a research note on Thursday. They issued a “buy” rating and a $8.00 price target for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Innate Pharma in a research note on Thursday, January 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Innate Pharma presently has an average rating of “Moderate Buy” and an average price target of $5.00.

Innate Pharma Price Performance

Shares of NASDAQ:IPHA remained flat at $1.50 during trading on Friday. 38,792 shares of the stock were exchanged, compared to its average volume of 15,063. The company has a 50 day moving average price of $1.71 and a two-hundred day moving average price of $1.86. Innate Pharma has a 1 year low of $1.40 and a 1 year high of $2.63.

About Innate Pharma

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.